Bvf Partners L.P.

Bvf Partners L.P.

BVF Partners was founded in 1993 by Behzad Aghazadeh, a biotech specialist who previously worked at Hambrecht & Quist. The firm began as a healthcare-focused hedge fund and has since evolved into a family-office-structured asset manager with a single-family-office posture, though it manages capital for the Aghazadeh family alongside institutional capital (per public filings). The firm's strategy centers on concentrated public equity investing in biotechnology and pharmaceutical companies, with a documented track record of holding large positions in firms developing novel therapeutics. BVF also invests in private placements, PIPEs, and registered direct offerings, often taking board seats. In 2023, BVF held major positions in companies such as Sarepta Therapeutics, Ionis Pharmaceuticals, and Arvinas (per SEC 13F filings, 2023). Across its portfolio, BVF targets companies with high scientific risk but potentially transformative drug candidates, particularly in oncology, rare diseases, and neurology. BVF operates from a global network of 11 offices spanning North America, Europe, and Asia, with hubs in Menlo Park, New York, London, Shanghai, and Geneva. The firm's total headcount is not publicly disclosed, but it fields a large team of analysts and portfolio managers with scientific backgrounds. The Aghazadeh family also maintains the BVF Foundation, a philanthropic vehicle that funds biomedical research and education (per the BVF Foundation website, 2024). In July 2024, BVF Partners led a $150 million Series B financing in Repertoire Immune Medicines, a biotech developing T cell receptor-based therapies (per FierceBiotech, July 2024). A structural differentiator is BVF's deep integration of scientific expertise into investment decisions — the firm employs PhDs and MDs who evaluate drug mechanisms directly. This model allows BVF to make concentrated bets where the market underappreciates clinical data, often during early-stage trial readouts.